|
KMID : 1202020090020020105
|
|
Journal of Korean Thyroid Association
2009 Volume.2 No. 2 p.105 ~ p.113
|
|
|
Effects of Sunitinib on the Growth and Invasion of Thyroid Papillary Cancer Cell Line
|
|
Han Doo-Hee
Choi Hyun-Jeung
Kim Won-Gu
Kim Eui-Young
Kim Tae-Yong
Kim Won-Bae
Shong Young-Kee
Yoon Jong-Ho
|
|
|
Abstract
|
|
|
Background and Objectives :Thyroid papillary cancer was known to have a good prognosis but it could have poor prognosis if there is local invasion or metastasis. Sunitinib, a multitargeted tyrosine-kinase inhibitor, has been reported to have an anticancer effect in experimental and clinical studies. In this study, we evaluated the effect of sunitinib on cell growth, migration, adherence in papillary thyroid cancer cell.
Materials and Methods : We have evaluated the effect of sunitinib on TPC-1 (papillary thyroid cancer cell) and NPA (melanoma cell). Expression of target gene was evaluated by reverse transcriptase polymerase chain reaction (RT-PCR) and immunoblot. Cell viability was measured by colorimetric assay and invasiveness of cancer cell was measured by migration assay and by anchorage independent growth assay. The change of protein level associated with cell proliferation and cell cycle were evaluated by immunoblot assay.
Results: The expression of vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor receptor (PDGFR) were more prominent in NPA cell than TPC-1 cell. The proliferation of cancer cells were decreased by sunitinib in dose-dependent manner and NPA cell was more susceptible to sunitinib. The migration and anchoring dependent growth of cancer cells were more decreased in NPA cell by sunitinib. Cyclin inhibitor, p21Waf1/Cip1 and p27Kip1 were suppressed by sunitinib only in TPC-1 cell, but not in NPA cell.
Conclusion: Sunitinib suppressed cancer cell proliferation and migration in NPA and TPC-1 cell. Sunitinib was less sensitive in papillary thyroid cancer cell than malignant melanoma cell. This difference could be related with suppression of p21Waf1/Cip1 and p27Kip1 by sunitinib in TPC-1 cell.
|
|
|
KEYWORD
|
|
|
Thyroid cancer, Papillary carcinoma, Sunitinib, Tyrosine kinase inhibitor, p21Waf1/Cip1, p27Kip1
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|